3School of Allied Medical Sciences (Hemat Highway , Next Milad Hospital , Tehran Medical Sicence University, Paramedics College ,Tehran - Iran Tel: +982188622766 Fax :+98188622533 E-mail : paramed_sec@tums.ac.ir - Iran)
Abstract : The tumor-associated glycoprotein 72 (TAG-72) is a membrane mucin whose over-expression is correlated with advanced tumor stage and increased invasion and metastasis. In this study, we identified a panel of four nanobodies, single variable domains of dromedary heavy-chain antibodies that specifically recognize the TAG-72 antigen. All selected nanobodies were shown to selectively bind to this cancer-related molecule with low-nanomolar affinities and do not cross-react with other antigens, such as MUC1 or HER2. Furthermore, they can detect TAG-72 in concentrations as low as 5 U/ml which is valuable in sensitive detection of this molecule in cancerous patients. Cell ELISA experiments proved their ability for binding to the native target antigen on TAG-72 expressing cells while not showing any reactivity to HT-29 cells, a TAG-72-negative cell line. Using competition studies, we found that each nanobody recognizes a distinct epitope on the TAG-72 antigen that is different from the one recognized by the mouse anti-TAG-72 antibody, CC49. Considering their high specificity, reduced immunogenicity and multi-targeting behavior, these oligoclonal nanobodies represent a promising tool to target TAG-72 over-expressing tumor cells.
https://hal-riip.archives-ouvertes.fr/pasteur-00825965 Contributor : Fereidoun MahboudiConnect in order to contact the contributor Submitted on : Saturday, May 25, 2013 - 9:01:04 AM Last modification on : Friday, May 13, 2022 - 2:18:02 PM Long-term archiving on: : Tuesday, April 4, 2017 - 11:18:14 AM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais
Zahra Sharifzadeh, Fatemeh Rahbarizadeh, Mohammad Ali Shokrgozar, Davoud Ahmadvand, Fereidoun Mahboudi, et al.. Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen.. Molecular Biotechnology, Humana Press, 2013, 54 (2), pp.590-601. ⟨10.1007/s12033-012-9601-0⟩. ⟨pasteur-00825965⟩